Portfolio

Autolus is a biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T effector cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Beacon is a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Syncona launched Beacon in June 2023, having invested £75 million of the £96 million Series A financing. As part of this Series A financing, AGTC was combined with new Syncona company, Beacon Therapeutics, merging AGTC’s lead clinical gene therapy asset with two exciting pre-clinical programmes, including one from the University of Oxford. In July 2024 Syncona committed an additional $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing, bringing the total amount that Beacon has raised in funding to date to approximately $290 million.

iOnctura is a clinical-stage oncology company developing innovative therapies for neglected and hard-to-treat cancers.

Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions.

Quell Therapeutics was founded with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system.

Anaveon is a clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.

Resolution is developing macrophage cell therapies to repair inflammatory organ damage.

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.

Forcefield is a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction (heart attacks). Myocardial infarction (MI) triggers the irreversible loss of large numbers of cardiomyocytes, or heart cells, which can lead to a cascade of events leading to heart failure. Up to 30% of cardiomyocytes can be lost during and immediately after MI.

OMass Therapeutics is an Oxford University spin-out that is using novel biochemistry techniques, native mass spectrometry and custom chemistry to deliver novel medicines against highly validated but inadequately drugged targets, with a focus on immunological and rare diseases.

Based in Cambridge, UK, Mosaic is an oncology therapeutics company with a highly specialised drug discovery platform, focused on discovering, developing and commercialising novel, targeted, therapies to target cancers in areas of high unmet need. Syncona led a £22.5 million Series A financing of the company in 2022, committing £16.5 million alongside Cambridge Innovation Capital.

Kesmalea is a small molecule drug discovery company established with the aim of creating a new generation of oral drugs addressing diseases through modulating protein homeostasis. Syncona led a £25 million Series A financing in the company in 2022, committing £20 million alongside Oxford Science Enterprises. An additional £5.0 million was raised in 2023 with Syncona committing £4.0 million.

Yellowstone is pioneering soluble T-cell receptor (TCR)-based therapies to unlock a new class of cancer therapeutics.

Slingshot, the Syncona Accelerator, is focused on accumulating a pipeline of early-stage programmes, identified from world-leading academic institutions, and accelerating their development towards the clinic.